Kenvue Inc. KVUE
Kenvue is an iconic consumer-health portfolio underperforming its potential — fixing margins and Skin Health & Beauty execution can close a wide valuation gap to Haleon and staples peers.
Thesis
Kenvue, the J&J consumer-health spinoff, owns category-leading franchises like Tylenol, Listerine, Band-Aid, Neutrogena and Aveeno but trades at a meaningful discount to pure-play consumer-health peer Haleon and to the broader staples complex. Starboard argues the gap reflects fixable operational weakness rather than asset quality: operating margins trail peers, marketing reinvestment has been sub-scale, and Skin Health & Beauty (notably Neutrogena and Aveeno) has lost share since the spin. Improving brand support, pricing and cost discipline could lift margins and earnings power, and a successful turn would compress the multiple gap to peers, generating substantial upside. The deck frames Kenvue as a high-quality, high-conviction self-help story where management execution — not portfolio surgery — is the unlock.
SCQA
Kenvue is the world's largest pure-play consumer-health company, spun from Johnson & Johnson in 2023, with iconic brands across OTC pain, oral care, skin care and first aid.
Since the spin Kenvue has trailed peers on margins and lost share in Skin Health & Beauty, leaving the stock at a meaningful discount to Haleon and the staples complex despite a category-leading portfolio.
Management should rebuild brand investment, fix execution in Skin Health & Beauty, drive cost and pricing discipline, and lift operating margins toward consumer-health peer benchmarks.
Closing the operating-margin and multiple gap to peers could deliver substantial upside, re-rating Kenvue closer to Haleon and the staples complex as earnings power is restored.
The three reasons
- 1
Kenvue owns iconic brands (Tylenol, Listerine, Band-Aid, Neutrogena) trading at a steep discount to peers
- 2
Operating margins lag Haleon and consumer-staples peers by hundreds of basis points
- 3
Skin Health & Beauty has lost share post-spin and is the clearest self-help opportunity
Primary demands
- Improve operating margins toward consumer-health peer benchmarks
- Reinvigorate brand investment and marketing execution, particularly in Skin Health & Beauty (Neutrogena, Aveeno)
- Reverse market-share losses post-J&J spinoff and recapture lost shelf and pricing power
- Drive a multiple re-rating closer to pure-play consumer-health peers
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notes
PDF file is corrupted/truncated at exactly 1,048,576 bytes (1 MB) — pdfinfo, pdftotext and pypdf all fail to parse the trailer/XRef, so no pages could be read. Identity, parties and date are inferred from the filename (Starboard Value, Kenvue, Active-Passive Investor Summit, Feb 2024 — Jeff Smith of Starboard presented the Kenvue thesis at 13D Monitor's Active-Passive Investor Summit on 2024-02-13). Thesis content (top_3_reasons, SCQA, KPIs, peers, demands) is reconstructed from widely-reported public coverage of Starboard's Kenvue campaign, NOT from the deck itself. Specific stake size, target price, page-level slide picks, and visual-craft scoring could not be verified — visual_quality and layout_density set to Starboard's typical institutional default; notable_slide_pages left empty. Recommend re-ingesting a clean copy of the file before treating any narrative field as authoritative.